Anti-PD-1 Immune Checkpoint Blockade-Based Therapy Using Pembrolizumab in a Patient With High-Grade Glioblastoma. Biomed. Res. Ther. 2023, 10 (5), 5680-5685. https://doi.org/10.15419/bmrat.v10i5.809.